Annual General Meeting of Fresenius Medical Care: Company on clearly defined path to transformational turnaround and to further unlocking value as leading kidney care company

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, is on a defined path of turning around the performance, and has outlined its strategy, as Helen Giza, CEO of Fresenius Medical Care, reported at today’s Annual General Meeting. “Our strategic roadmap starts with having an optimal structure in place”, Giza said in her speech to the shareholders, referring to the new operational model, which is in effect since January 1, 2023, and the proposed change of the legal form, which will be decided upon in an extraordinary general meeting on July 14, 2023. “We are just at the beginning of a new chapter in Fresenius Medical Care’s history, and I am energized and excited about our clear transformational turnaround plan under execution, supported by our 125,000 employees around the world. By 2025, Fresenius Medical Care will not only be a more agile and more resilient company, but also remain the partner of choice, setting the standard in kidney care with industry leading returns.”

“There is no other global healthcare company with our expertise, scope, and scale in kidney care. Fresenius Medical Care is uniquely positioned to meet the demands for kidney care on a global basis”, Helen Giza said. “Today, our predictive analytics capabilities and continuous enhancement of medical algorithms are key parameters for improving the quality of outcomes and quality of life for our patients.”

A large shareholder majority of 99.99 percent approved the dividend proposal of €1.12, which reflects a reduction by 17 percent compared to the previous year, in line with the policy to align dividend payments with earnings development.
Shareholder majorities of 99.09 and 91.46 percent, respectively, approved the actions of the General Partner and the Supervisory Board in 2022.

At the Annual General Meeting, 87.12 percent of the registered capital was represented. The meeting again was held as a purely virtual event.

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.